Syrma SGS has transformed from a niche electronics manufacturer into one of India's fastest-growing diversified EMS companies. Over FY23-FY26, it has scaled consolidated revenue from ~₹2,100 Cr to a projected ~₹4,500+ Cr while expanding EBITDA margins from 7% to 12.6% (Q3 FY26). The company has executed a deliberate strategy of shifting mix from low-margin consumer electronics towards higher-margin segments (Industrial, Automotive/EV, Healthcare, Defence), supported by both organic growth and targeted acquisitions.
Syrma SGS has undergone a remarkable transformation from a niche precision electronics manufacturer into a diversified, design-led EMS powerhouse. The company's journey can be tracked through three distinct phases.
| Dimension | FY23 (Then) | FY26 (Now) |
|---|---|---|
| Core Identity | EMS manufacturer | Design-led electronics solutions provider |
| Revenue Mix | Consumer-heavy (~40%) | Balanced: Industrial 35%, Auto 25%, Consumer 25%, Healthcare/Defence 15% |
| Capacity Approach | Customer-driven (build to order) | Ahead-of-time campus investment |
| ODM Share | ~12% of revenue | ~38% of revenue (H1 FY26) |
| Export Mix | ~30% (declining) | 25% and growing to 33% target |
| Manufacturing Footprint | North & South India | Pan-India + Germany + USA operations |
| No. of Facilities | ~15 | 18+ including international |
| Verticals Served | Consumer, Auto, Industrial, RFID | +MedTech, Defence, Railways, Solar, Smart Metering |
| Metric | FY23 | FY24 | FY25 | 9M FY26 | FY26E* |
|---|---|---|---|---|---|
| Revenue (₹ Cr) | 2,048 | 3,154 | 3,787 | 3,354 | ~4,600 |
| YoY Growth | - | +54% | +20% | +34% | ~+22% |
| EBITDA (₹ Cr) | ~150 | 257 | 324 | 370 | ~500+ |
| EBITDA Margin | ~7.3% | 8.0% | 8.6% | 11.0% | ~10%+ |
| PAT (₹ Cr) | 123 | 124 | 184 | 227 | ~300+ |
| PAT Margin | 6.0% | 3.9% | 4.9% | 6.8% | ~6.5% |
| EPS (₹) | 7.59 | 6.06 | 9.55 | ~12.7 | ~17 |
*FY26E = Estimated based on 9M run-rate and management guidance. Revenue in ₹ Crores.
| Quarter | Revenue (₹ Cr) | EBITDA Margin | PAT (₹ Cr) | YoY Rev Growth |
|---|---|---|---|---|
| Q2 FY24 | 486 | 7.0% | - | - |
| Q3 FY24 | 530 | 7.5% | - | - |
| Q4 FY24 | 612 | 7.8% | - | - |
| Q1 FY25 | 640 | 5.2% | 20 | +52% |
| Q2 FY25 | 834 | 8.8% | 40 | +17% |
| Q3 FY25 | 892 | 9.1% | 53 | +24% |
| Q4 FY25 | 947 | ~8.5% | - | +6% QoQ |
| Q1 FY26 | 932 | 10.0% | 50 | +25% |
| Q2 FY26 | ~1,050 | ~9% | 66 | +36% exp |
| Q3 FY26 | ~1,150+ | 12.6% | 110 | +108% |
| Metric | FY24 | FY25 | Assessment |
|---|---|---|---|
| Total Equity (₹ Cr) | 1,442 | 1,498 | Adequate |
| Gross Debt (₹ Cr) | ~514 | ~313 | Reducing |
| Cash & Equivalents (₹ Cr) | ~320 | ~227 | Adequate |
| Net Debt/Equity | 0.31x | 0.19x | Conservative |
| Working Capital Days | 70 | 56 | Improving |
| ROE | ~8.6% | ~11.5% | Expanding |
| ROCE (Adj.) | ~10% | ~13% | Expanding |
| OCF (₹ Cr) | -109 | +176 | Turnaround |
Syrma's growth is predominantly organic (core EMS business expansion + new customer wins), supplemented by strategic acquisitions that fill specific capability gaps rather than buying revenue.
| Acquisition | Year | Stake | Cost (₹ Cr) | What It Does | Strategic Rationale | EBITDA Margin |
|---|---|---|---|---|---|---|
| Perfect ID | FY23 | 100% | Small | RFID technology, identity solutions | Strengthen RFID product portfolio | - |
| Johari Digital (now Syrma Johari Medtech) | FY24 | 51% | ~250 | Medical device ODM; 15-18 FDA approvals | Enter MedTech; acquire regulatory moat | 30%+ |
| Ekome/Elcome | Q3 FY26 | 60% | ~235 | Defence: navigation, surveillance, comms | Enter Defence sector; high-margin | ~24-25% |
| KSolare (JV) | FY26 | 49% | - | Solar inverters (rooftop & utility) | Enter renewable energy segment | - |
| Period | New Customers Added | Revenue Potential | Key Verticals |
|---|---|---|---|
| FY23 | 8-10 major customers | Multi-year revenue streams | Auto, Industrial, Power, Energy Metering, Lighting |
| FY24 | 10+ customers | Series production CY2024 | IoT, Utility Metering (US), HVAC (Germany) |
| H1 FY25 | 9 new clients | ₹500+ Cr potential | Power supply, smart metering, fuel, IoT, Auto |
| FY25 Total | 20-25 customers | - | Broad-based across all segments |
| H1 FY26 | Continued momentum | - | Auto, Industrial, Defence (post Elcome) |
| Segment | FY23 Share | FY25 Share | FY26 Target | FY25 Growth | Margin Profile | Outlook |
|---|---|---|---|---|---|---|
| Consumer Electronics | ~40% | ~30% | 25-30% | +7% | Low (9-10%) | Deliberately being reduced; build-to-print; volume game |
| Industrial | ~20% | ~28% | 30-35% | +29% | Medium-High | Smart metering, power supplies, automation - strong tailwinds |
| Automotive & EV | ~20% | ~22% | 25% | +26% | Medium-High | Tier-1 in EV; BMS, chargers, EV components growing fast |
| Healthcare/MedTech | ~2% | ~5% | 7-8% | +297% | Very High (30%+) | Johari acquisition driving; PLI approvals; global demand |
| Railways & IT | ~3% | ~7% | 8-10% | +58% | High | RDSO approval obtained; long gestation but high-margin |
| RFID & Magnetics | ~8% | ~5-7% | 5% | Stable | Medium | Mature; steady contributor; proprietary products |
| Defence (NEW - Elcome) | - | - | 3-5% | New | Very High (24-25%) | Acquired Q3 FY26; navigation, surveillance, communications |
Emerged as a significant sub-segment. Syrma is one of the largest contract manufacturers for utility meters (19-year track record). Domestic smart meters: 1.3M units sold in H1 FY25. Export utility metering to USA started September 2024. Expected ₹250-300 Cr domestic + ₹100+ Cr export contribution by FY27.
Positioned as Tier-1 supplier in EV (vs. Tier-2 in traditional auto) which brings incremental margin uplift. Focus on battery management systems, charging infrastructure, and EV power electronics. EV auto segment grew 65-70% in FY23 and continues to outpace traditional auto.
40-year-old acquired company with 15-18 FDA approvals. Focus areas: cancer care/radiotherapy, anesthetics, cardiorespiratory, renal care devices. PLI approval received for two MedTech segments. Dedicated Pune Design Centre commissioned. Global customer traction from Europe, Japan, and America. Revenue target: ₹375-400 Cr by FY26.
| Name | Role | Background |
|---|---|---|
| Sandeep Tandon | Executive Chairman | Co-founder; strategic vision; coined "Y2K moment for EMS" thesis |
| Jasbir Singh Gujral | Managing Director | Co-founder & Promoter; 40+ years in electronics; ICAI Fellow; holds 7.04% stake |
| Satendra Singh | CEO | Operational leader; driving "build for future" strategy; campus-level investment approach |
| Bijay Agrawal | CFO | Financial discipline; working capital optimization; conservative guidance philosophy |
| Period | What They Guided | What They Delivered | Verdict |
|---|---|---|---|
| FY23 Revenue | Exceed 40% industry growth | 63% growth achieved | Beat |
| FY24 Revenue | ₹3,000 Cr | ₹3,154 Cr | Beat |
| FY24 EBITDA Margin | 7-7.5% | 6.9% (slight miss due to consumer mix) | Slight Miss |
| FY25 Revenue | ₹4,500 Cr (40-45% growth) | ₹3,837 Cr (19% growth) | Missed (macro headwinds) |
| FY25 EBITDA Margin | 7% | 8.6% (FY25 exit rate ~9.1%) | Beat significantly |
| Working Capital | 60 days target | 56 days achieved | Beat |
| FY26 EBITDA | ₹400 Cr initially | Revised to ₹500+ Cr (9M already at ₹370 Cr) | Upgraded |
| Export Growth | 20% YoY | 45% YoY in 9M FY26 | Beat significantly |
| Pune Campus | Commission by Q2 FY25 | Commissioned October 2024 | On time |
| Phase | Period | Core Thesis |
|---|---|---|
| "Y2K Moment" | FY23 (IPO era) | India is the next China for electronics manufacturing. Build capacity to capture MNC sourcing shift. |
| "Scale & Diversify" | FY24 | Acquire MedTech capabilities (Johari). Double SMT capacity. Add segments to reduce concentration. |
| "Build for the Future" | FY25 | Invest ahead of demand (Pune campus). Shift to higher-margin segments. Reduce consumer dependency. |
| "Profitability Focus" | FY26 | Harvest margin expansion from mix shift. Enter Defence. Target ₹10,000 Cr revenue in few years. EBITDA margin 10%+ sustainable. |
| Category | FY23-FY26 Spend (₹ Cr) | Purpose | Assessment |
|---|---|---|---|
| Organic Capex | ~650-700 | SMT lines, Pune campus, Noida, Manesar, Germany | Productive - Doubled capacity; high utilization |
| Acquisitions | ~485 | Johari MedTech (₹250 Cr) + Elcome Defence (₹235 Cr) | Strategic - High-margin verticals; regulatory moats |
| Working Capital | ~500 | Inventory + receivables for growth | Necessary - Days improving (89→56) |
| Dividends | ~53 | ₹1.50/share in FY24 and FY25 | Token - Growth-focused; low payout |
| Purpose | Planned (₹ Cr) | Utilized till Dec 2025 | Remaining |
|---|---|---|---|
| Capex | 403 | 352 | 51 |
| Working Capital | 120 | 132 | ~0 |
| General Corporate | 103 | 190 | - |
| Total | 726 | 673 | ~52 |
One of Syrma's most transformative strategic moves is its backward integration into Printed Circuit Board (PCB) and Copper Clad Laminate (CCL) manufacturing. PCBs are the single largest imported input for any EMS company, and India imports ~95% of its PCB needs. Syrma is setting up what will be India's largest multi-layer PCB manufacturing facility under the government's ECMS scheme.
| Parameter | Details |
|---|---|
| Project Entity | Syrma Strategic Electronics Pvt. Ltd. (SSEPL) - subsidiary of Syrma SGS |
| JV Partner | Shinhyup Electronics Ltd. (South Korea) - 3.5+ decades of PCB manufacturing expertise; provides technology & marketing support |
| Location | Menakuru village, Naidupeta, Tirupati District, Andhra Pradesh |
| Land Allotted | 26.70 acres (allotted at 75% subsidised cost under AP policy) |
| Total Investment | ₹1,800 Crore (phased over multiple years) |
| ECMS-Approved Investment | ₹765 Crore (approved October 27, 2025 by Engineers India Ltd / MeitY) |
| Start of Eligible Investment | April 8, 2025 |
| Trial Production | December 2026 |
| Commercial Production | March 2027 (FY27) |
| Full-Scale Operations | FY28 (2027-28) |
| Jobs Created | 2,100+ direct jobs (1,000+ at PCB unit; rest at CCL & ancillary units) |
| Project | Investment (₹ Cr) | Products | Significance |
|---|---|---|---|
| 1. PCB Manufacturing & R&D Unit | ~1,076 | Single-layer, Multi-layer, HDI, and Flexible PCBs | India's largest PCB facility; covers entire complexity spectrum |
| 2. CCL Manufacturing Unit | ~320 | Copper Clad Laminates (key PCB raw material) | Further backward integration; reduces import dependency |
| 3. Ancillary & Support Infrastructure | ~197 | ETP, utilities, testing labs, logistics | Complete ecosystem within campus |
| Total Naidupeta Complex | ~1,593 | Comprehensive PCB + CCL manufacturing ecosystem | |
| Incentive Component | Details |
|---|---|
| Central ECMS PLI | 4% to 10% on revenue during benefit period (6 years: FY27 to FY32) |
| Expected Production Value | ₹6,933 Crore cumulative over the incentive period |
| AP State Incentives | ₹856 Cr comprehensive incentive package under AP Electronics Components Manufacturing Policy 4.0 (2025-30) |
| Land Subsidy | 12.56 acres at 75% subsidised cost in Naidupeta industrial area |
| Additional State Support | Capital subsidies, power support, and tax-linked enablers |
| Total Govt. Support | Central PLI (4-10% of revenue for 6 yrs) + State incentives (₹856 Cr package) |
| Year | PCB Capacity (M sq.m) | Est. Revenue (₹ Cr) | EBITDA Margin | PLI Benefit (4-10%) | Notes |
|---|---|---|---|---|---|
| FY27 (H2 only) | ~0.5 | ~150-200 | ~12% | ~₹8-20 Cr | Trial → commercial ramp |
| FY28 | ~1.5-2.0 | ~500-700 | ~15% | ~₹20-70 Cr | Full-scale; multi-layer + HDI begins |
| FY29 | ~2.5 | ~800-1,000 | ~16% | ~₹32-100 Cr | Advanced products; flexible PCBs |
| FY30-32 | ~2.5+ | ~1,000-1,500 | ~16-17% | Ongoing | Steady state; ₹6,933 Cr cumulative target |
Estimates based on management commentary, ECMS filing (₹6,933 Cr production value), and industry benchmarks. Not investment advice.
| Moat Type | Strength | Durability | Comments |
|---|---|---|---|
| Switching Costs | High | Strong | 12-18 month qualification; FDA/RDSO approvals non-transferable |
| Scale Advantage | Medium | Moderate | Growing but competitors (Dixon, Kaynes) also scaling fast |
| Intangible Assets (Regulatory) | High | Strong | FDA, RDSO, PLI approvals = multi-year barriers |
| Network Effects | Low | Weak | EMS industry has limited network effects |
| Cost Advantage | Medium | Moderate | India cost arbitrage vs. China; improving with scale |
| Vertical Integration (PCB) | High | Strong | Only Indian EMS with CCL→PCB→Assembly integration under ECMS; ₹1,800 Cr investment creates structural cost advantage |
| Metric | Value | Assessment |
|---|---|---|
| Top 20 Customers Revenue Share (Q2 FY26) | 72% | Moderate Risk |
| Any Single Customer >10% | Yes (disclosed in annual report) | Concentration exists |
| New Customers Added (FY25) | 20-25 | Active Diversification |
| Customer Base | 300+ customers | Broad Base |
| Sector Diversification | 7+ verticals | Well Diversified |
| Period | Export % | Export Revenue | YoY Growth | Target |
|---|---|---|---|---|
| FY23 | ~30% | - | - | - |
| FY24 | 26% | ~₹860 Cr | - | - |
| FY25 | 22.4% | ₹860 Cr | Flat | ₹1,000+ Cr |
| 9M FY26 | 25% | ₹837 Cr | +45% | 33% long-term |
| Q3 FY26 (quarter) | ~29% | ₹335 Cr | +66% | Record quarter |
As an EMS/ODM company, Syrma's IP is different from a product company. Their IP lies in design capabilities, manufacturing process expertise, regulatory approvals, and increasingly in ODM product platforms.
| IP Category | Details | Revenue Impact | Moat Value |
|---|---|---|---|
| ODM Product Designs | Medical device platforms via Johari (cancer care, radiotherapy, anesthetics, renal care); Growing from 12% to 38% of revenue | High - 38% of H1 FY26 revenue | Strong |
| RFID Products | Proprietary RFID tags, inlays, magnetic components; Global delivery | Medium - 5-7% of revenue | Moderate |
| FDA/Regulatory Approvals | 15-18 FDA approvals (medical devices); RDSO (railways); AS9100D (aerospace) | Growing | Very Strong (3-5 year barrier) |
| Manufacturing Process IP | SMT expertise; testing automation; Poka-Yoke systems; smart manufacturing | Embedded in margins | Moderate |
| Quality & Testing Systems | Quality assurance services; regulatory approval services (new revenue streams) | Emerging | Growing |
| Defence Electronics IP (Elcome) | Navigation, surveillance, communication solutions; 50-year track record | New (Q3 FY26) | Strong (Defence clearances) |
| Metric | FY25 (Actual) | FY26E | FY27E | FY28E |
|---|---|---|---|---|
| Revenue (₹ Cr) | 3,837 | ~4,600 | ~6,000-6,500 | ~8,000-8,500 |
| Revenue Growth | 19% | ~22% | ~30-35% | ~30% |
| EBITDA (₹ Cr) | 324 | ~500+ | ~650 | ~850+ |
| EBITDA Margin | 8.6% | ~10%+ | ~10-11% | ~10-11% |
| PAT (₹ Cr) | 184 | ~300+ | ~400-430 | ~550+ |
| Export Revenue (₹ Cr) | 860 | ~1,100+ | ~1,500+ | ~2,200+ |
Projections based on management guidance, order book visibility, capacity installed, and current growth trajectory. Not investment advice.
| Risk | Severity | Probability | Mitigation |
|---|---|---|---|
| Customer Concentration Top 20 = 72% of revenue |
Medium-High | Medium | Adding 20-25 customers/year; vertical diversification; export expansion |
| Acquisition Integration Risk Johari + Elcome + KSolare simultaneously |
Medium | Low-Medium | Maintaining existing management; operational autonomy model; phased integration |
| European Recession Germany "sick baby of EU"; subdued export demand |
Medium | Medium | Diversifying to USA and Japan; long-term structural positioning |
| Margin Sustainability Q3 FY26's 12.6% may be peak; consumer volatility |
Medium | Low-Medium | Structural mix shift; management guiding 10% as sustainable; ODM growth |
| Competition Intensifying Dixon, Kaynes, Amber, SFO also scaling |
Medium | Medium | Differentiation through design capabilities, MedTech niche, regulatory approvals |
| Capex Execution Risk Pune, Hosur, PCB, Germany running concurrently |
Medium | Low | Track record of on-time delivery; phased approach; Pune already commissioned |
| Supply Chain / Semiconductor Risk Heavy import dependence on components |
Medium | Low | Centralized supply chain; multiple vendor relationships; PCB backward integration |
| US Tariff / Geopolitical Volatility Changing trade policies affect export economics |
Medium | Medium | Domestic market as anchor; Germany facility for EU access; diversified markets |
| Key Man Risk MD Jasbir Singh Gujral approaching 70 years |
Low-Medium | Low | CEO Satendra Singh increasingly driving operations; professional management team |
Syrma SGS is a well-managed, fast-growing Indian EMS company executing a successful transformation from a commoditized build-to-print manufacturer to a design-led, diversified electronics solutions provider.
Mix shift sustains 10%+ EBITDA margins. Revenue hits ₹8,000+ Cr by FY28. Exports reach 33% of revenue. Defence and MedTech become ₹1,000+ Cr segments. ODM at 40%+ creates structural margin advantage. EPS could reach ₹30+ by FY28.
Consumer segment drag returns; margins revert to 7-8%. Customer concentration causes revenue volatility. Acquisition integration issues with Elcome/KSolare. European recession deepens. Competition compresses pricing. Growth slows to 15-20%.
Analysis based on 3 Annual Reports (FY23-FY25), 15 Concall Transcripts (Q2FY23-Q3FY26), and Q3FY26 Quarterly Results. This is an analytical report, not investment advice.